FY27 Revenue Guidance of ₹370-380 Cr
Management expects consolidated revenue of ₹370-380 Cr for FY27, driven by existing operations and acquisitions, with potential upside.
ANLONHEALTHCARE / guidance tracker
Keep management guidance in view.
Anlon Healthcare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
30% Revenue CAGR Over Next 3 Years
Company targets approximately 30% revenue CAGR over the next three years, supported by capacity expansion and new product launches.
Blended EBITDA Margin of 32-33%
Consolidated EBITDA margin expected to be 32-33% going forward, with Enlon at 35%+ and Epico at ~30%.
Greenfield Capex of ₹100-120 Cr
Company plans ₹100-120 Cr capex for greenfield expansion, funded by internal accruals (₹40-50 Cr) and bank debt (₹50-60 Cr), to be completed by March 2027.